


Phase III PHOENYCS-GO trial:
Dapirolizumab pegol in SLE (NCT04294667)

N = 321

Primary endpoint: **BICLA response at Week 48**
Eligibility: Aged ≥16 years with moderate-to-severe, active SLE despite stable SoC medication

STUDY DESIGN



EFFICACY

Treatment arm, n = 208Control arm, n = 107

